OCUL
Ocular Therapeutix Inc
7.00$
-4.5%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 70.0% | – | 11.8% | 18.2% | 23.5% | 23.8% | 23.4% | 55.0% | 12.0% | 10.1% | 8.8% | 9.0% | 8.8% | 12.7% | |
| 30.0% | – | 88.2% | 81.8% | 76.5% | 76.2% | 76.6% | 45.0% | 88.0% | 89.9% | 91.2% | 91.0% | 91.2% | 87.3% | |
| 115,400.0% | – | 2,445.6% | 1,520.6% | 1,434.3% | 1,605.8% | 1,855.0% | 972.1% | 164.9% | 115.1% | 103.8% | 104.5% | 200.3% | 380.3% | |
| 14,770.0% | – | 895.5% | 523.7% | 583.1% | 806.5% | 944.0% | 523.3% | 131.4% | 73.3% | 132.0% | 58.1% | 95.2% | 124.2% | |
| 136,740.0% | – | 3,597.8% | 2,264.5% | 2,372.5% | 3,296.4% | 3,047.4% | 2,074.9% | 449.2% | 269.2% | 243.9% | 231.9% | 360.7% | 608.6% | |
| -136,710.0% | – | -3,509.6% | -2,182.7% | -2,296.0% | -3,220.1% | -2,970.8% | -2,029.9% | -361.1% | -179.3% | -152.7% | -141.0% | -269.6% | -521.0% | |
| 3,770.0% | – | 144.9% | 98.5% | 89.0% | 98.4% | 87.4% | 144.3% | 38.9% | 15.3% | 13.6% | 19.4% | 21.3% | 22.8% | |
| -140,930.0% | – | -3,710.9% | -2,271.3% | -2,369.0% | -3,296.2% | -3,014.0% | -2,043.3% | -894.3% | -15.1% | -138.0% | -138.1% | -303.7% | -513.2% | |
| 3,280.0% | – | 16.8% | 55.8% | 42.3% | 14.1% | -114.9% | 84.3% | 23.0% | 9.8% | -14.8% | 4.8% | – | – | |
| -140,930.0% | – | -3,710.9% | -2,271.3% | -2,369.0% | -3,296.2% | -2,899.1% | -2,043.3% | -894.3% | -15.1% | -138.0% | -138.1% | -303.7% | -513.2% | |
| -133,120.0% | – | -3,495.1% | -2,129.7% | -2,233.3% | -3,113.3% | -2,811.7% | -1,839.2% | -839.5% | 5.8% | -120.2% | -113.6% | -276.4% | -482.0% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.